A team of researchers from NYU Abu Dhabi and the University of Denver has identified a promising small molecule that could ...

– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MSA is a progressive ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

CHICAGO, March 26, 2026 /PRNewswire-PRWeb/ -- Mission MSA is proud to announce its 2026 designated MSA Centers of Excellence (COE), a prestigious network of clinical institutions recognized for their ...

A Midlothian mum has opened up on the day her 'life changed' at being told she is dying. Angela Lynch, 54, was diagnosed with ...

Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced the launch of “Power in the Periphery,” a new disease education campaign for healthcare professionals (HCPs) to raise awareness and deepen ...

CurePSP hosted a congressional briefing this month in partnership with Representatives Subramanyam (D-VA) and Bilirakis (R-FL), bringing together lawmakers, scientists and people affected by ...

A team of researchers from NYU Abu Dhabi and the University of Denver has identified a promising small molecule that could help slow or halt the progression of serious brain diseases such as Parkinson ...

Good morning and welcome to the Theravance Biopharma KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Theravance website ...

– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MELBOURNE, Australia and SAN ...